[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  WhisperTick [@whispertickers](/creator/twitter/whispertickers) on x XXX followers Created: 2025-07-17 18:27:33 UTC The cannabis sector in 2025 is a tale of two markets. While US operators like Curaleaf $CURLF and Green Thumb $GTBIF thrive, Canadian firms such as Canopy Growth $CGC face perilous declines. • Curaleaf and Green Thumb benefit from vertical integration and consistent US market growth, yet face regulatory uncertainties. • Canopy struggles with an oversaturated market and persistent financial losses. Their shares have dropped nearly XX% since January. • Tilray's $TLRY diversification into non-cannabis sectors offers a buffer but leaves core business consistency in question. The potential US rescheduling of cannabis to Schedule III lurks as a catalyst—and a conundrum. Execution, not just hype, will separate winners from laggards. Discover more insights and what's next in our detailed analysis:  XXX engagements  **Related Topics** [$cgc](/topic/$cgc) [$weedto](/topic/$weedto) [$gtbif](/topic/$gtbif) [$curlf](/topic/$curlf) [Post Link](https://x.com/whispertickers/status/1945913278695133614)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
WhisperTick @whispertickers on x XXX followers
Created: 2025-07-17 18:27:33 UTC
The cannabis sector in 2025 is a tale of two markets. While US operators like Curaleaf $CURLF and Green Thumb $GTBIF thrive, Canadian firms such as Canopy Growth $CGC face perilous declines.
• Curaleaf and Green Thumb benefit from vertical integration and consistent US market growth, yet face regulatory uncertainties. • Canopy struggles with an oversaturated market and persistent financial losses. Their shares have dropped nearly XX% since January. • Tilray's $TLRY diversification into non-cannabis sectors offers a buffer but leaves core business consistency in question.
The potential US rescheduling of cannabis to Schedule III lurks as a catalyst—and a conundrum. Execution, not just hype, will separate winners from laggards. Discover more insights and what's next in our detailed analysis:
XXX engagements
/post/tweet::1945913278695133614